| Five Points Home Health | |
| 3107 Raeford Road, Fayetteville, North Carolina 28303 | |
| (910) 323-3628 | |
| Name | Five Points Home Health |
|---|---|
| Location | 3107 Raeford Road, Fayetteville, North Carolina |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 347241 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 27330, 27332, 27505, 28301, 28303, 28304, 28305, 28306, 28311, 28312, 28314, 28320, 28326, 28327, 28328, 28334, 28337, 28339, 28340, 28348, 28350, 28351, 28352, 28356, 28357, 28358, 28360, 28362, 28364, 28369, 28371, 28372, 28374, 28376, 28377, 28382, 28383, 28384, 28385, 28386, 28387, 28390, 28391, 28395, 28399, 28431, 28463 |
| NPI Number | 1700926292 |
| Organization Name | FIVE POINTS HEALTHCARE OF NC LLC |
| Doing Business As | AVEANNA HOME HEALTH |
| Address | 3107 Raeford Rd, Fayetteville, NC 28303 |
| Phone Number | 910-323-3628 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment, according to new research from the University of East Anglia.
British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
› Verified 4 days ago
| NPI Number | 1942660352 |
| Organization Name | FIVE POINTS HEALTHCARE OF NC, LLC |
| Doing Business As | FIVE POINTS HOME HEALTH |
| Address | 1540 Purdue Dr, Suite 302, Fayetteville, NC 28303 |
| Phone Number | 910-323-3628 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment, according to new research from the University of East Anglia.
British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
› Verified 4 days ago
| Quality Rating: |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment, according to new research from the University of East Anglia.
British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 97.5 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.9 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 95.9 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 87.9 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 92.4 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.4 | 96.4 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment, according to new research from the University of East Anglia.
British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 74.8 | 79.6 |
| How often patients got better at getting in and out of bed | 78.2 | 81.1 |
| How often patients got better at bathing | 81 | 82.3 |
| How often patients’ breathing improved | 82.8 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 95.8 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 70.7 | 75 |
| How often home health patients had to be admitted to the hospital | 18 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 14.5 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 99.3 | 94 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment, according to new research from the University of East Anglia.
British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
› Verified 4 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment, according to new research from the University of East Anglia.
British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
› Verified 4 days ago
The patient survey data of Five Points Home Health is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 90 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 83 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 88 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 86 | 78 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment, according to new research from the University of East Anglia.
British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
› Verified 4 days ago
Healthkeeperz Location: 4155 Ferncreek Drive, Fayetteville, North Carolina 28304 Ratings: Phone: (910) 860-4764 | |
Cape Fear Valley Home Health Location: 3400 Walsh Drive Suite 100, Fayetteville, North Carolina 28311 Ratings: Phone: (910) 609-6740 | |
Amedisys Home Health Of Fayetteville Location: 2021 Valley Gate Drive Suite 201, Fayetteville, North Carolina 28304 Ratings: Phone: (910) 483-6144 | |
Five Points Home Health Location: 3107 Raeford Road, Fayetteville, North Carolina 28303 Ratings: Phone: (910) 323-3628 | |
Liberty Home Care Location: 1830 Owen Drive Suite 103, Fayetteville, North Carolina 28304 Ratings: NA Phone: (910) 864-8411 |